Announcement of Meeting of the National Clinical Care Commission, 21347-21348 [2019-09920]

Download as PDF Federal Register / Vol. 84, No. 93 / Tuesday, May 14, 2019 / Notices khammond on DSKBBV9HB2PROD with NOTICES inspections conducted under 44 U.S.C. 2904 and 2906. 10. Information may be disclosed to a Member of Congress or a Congressional staff member in response to a written inquiry of the Congressional office made at the written request of the constituent about whom the record is maintained. The Congressional office does not have any greater authority to obtain records than the individual would have if requesting the records directly. 11. Records may be disclosed to the U.S. Department of Homeland Security (DHS) if captured in an intrusion detection system used by HHS and DHS pursuant to a DHS cybersecurity program that monitors internet traffic to and from federal government computer networks to prevent a variety of types of cybersecurity incidents. 12. Records may be disclosed to appropriate agencies, entities, and persons when (1) HHS suspects or has confirmed that there has been a breach of the system of records, (2) HHS has determined that as a result of the suspected or confirmed breach there is a risk of harm to individuals, HHS (including its information systems, programs, and operations), the federal government, or national security, and (3) the disclosure made to such agencies, entities, and persons is reasonably necessary to assist in connection with HHS’s efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm. 13. Records may be disclosed to another federal agency or federal entity, when HHS determines that information from this system of records is reasonably necessary to assist the recipient agency or entity in (1) responding to a suspected or confirmed breach or (2) preventing, minimizing, or remedying the risk of harm to individuals, the recipient agency or entity (including its information systems, programs, and operations), the federal government, or national security, resulting from a suspected or confirmed breach. The disclosures authorized by publication of the above routine uses pursuant to 5 U.S.C. 552a(b)(3) are in addition to other disclosures authorized directly in the Privacy Act at 5 U.S.C. 552a(b)(4)–(11). POLICIES AND PRACTICES FOR STORAGE OF RECORDS: Records are stored in hard-copy files and electronic media. POLICIES AND PRACTICES FOR RETRIEVAL OF RECORDS: Records are retrieved by the individual’s name. VerDate Sep<11>2014 16:57 May 13, 2019 Jkt 247001 POLICIES AND PRACTICES FOR RETENTION AND DISPOSAL OF RECORDS: Records pertaining to recruitment and use of outside peer reviewers are destroyed three years after final action; they are retained longer if required for business use (see General Records Schedule (GRS) 1.2, Item 010, Grant and Cooperative Agreement Program Management Records). Records pertaining to recruitment and use of other outside individuals (e.g., experts, patient advocates, and members of mission-related non-FACA committees) are currently unscheduled. Unscheduled records must be retained indefinitely pending the agency’s submission, and NARA’s approval, of a disposition schedule. HHS anticipates proposing to NARA, as an appropriate retention period for these records, ‘‘three years after final action, or longer if required for business use’’ (similar to the period provided in GRS 1.2, Item 010) or ‘‘when no longer needed for administrative purposes’’ (similar to the periods applicable to similar records not retrieved by personal identifier which are not covered under this SORN; i.e.: N1–442–93–1, Item 37 for the Agency for Toxic Substances and Disease Registry’s Curriculum Vitae Files, and NC1–235–82–1, Item 100–3 for the Office of the Secretary’s Advisory Committee Candidate Resume Files). ADMINISTRATIVE, TECHNICAL, AND PHYSICAL SAFEGUARDS: Safeguards conform to the HHS Information Security and Privacy Program, https://www.hhs.gov/ocio/ securityprivacy/index.html. Information is safeguarded in accordance with applicable laws, rules and policies, including the HHS Information Technology Security Program Handbook, all pertinent National Institutes of Standards and Technology (NIST) publications, and OMB Circular A–130, Managing Information As a Strategic Resource. Records are protected from unauthorized access through appropriate administrative, physical, and technical safeguards. These safeguards include protecting the facilities where records are stored or accessed with security guards, badges and cameras, securing hard-copy records in locked file cabinets, file rooms or offices during off-duty hours, limiting access to electronic databases to authorized users based on roles and two-factor authentication (user ID and password), using a secured operating system protected by encryption, firewalls, and intrusion detection systems, requiring encryption for records stored on removable media, and training personnel in Privacy Act and PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 21347 information security requirements. Records that are eligible for destruction are disposed of using destruction methods prescribed by NIST SP 800–88. RECORD ACCESS PROCEDURES: An individual seeking access to records about him or her in this system should submit a written request to the relevant System Manager indicated in the ‘‘System Manager(s)’’ section above. The requester must verify his or her identity by providing either a notarization of the request or a written certification that the requester is who he or she claims to be and understands that the knowing and willful request for acquisition of a record pertaining to an individual under false pretenses is a criminal offense under the Privacy Act, subject to a five thousand dollar fine. CONTESTING RECORD PROCEDURES: An individual seeking to amend a record about him or her in this system should contact the relevant System Manager indicated in the ‘‘Section Manager(s)’’ section, verify his or her identity in the manner indicated in the ‘‘Record Access Procedures’’ section, and reasonably identify the record, specify the information contested, state the corrective action sought, and provide the reasons for the amendment, with any supporting documentation. NOTIFICATION PROCEDURES: An individual who wishes to know if this system contains records about him or her should contact the relevant System Manager indicated in the ‘‘Section Manager(s)’’ section and verify his or her identity in the manner indicated in the ‘‘Record Access Procedures’’ section. EXEMPTIONS CLAIMED FOR THE SYSTEM: None. HISTORY: 81 FR 83246 (Nov. 21, 2016), 83 FR 6591 (Feb. 14, 2018). [FR Doc. 2019–09926 Filed 5–13–19; 8:45 am] BILLING CODE 4184–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Announcement of Meeting of the National Clinical Care Commission Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: The National Clinical Care Commission (the Commission) will SUMMARY: E:\FR\FM\14MYN1.SGM 14MYN1 21348 Federal Register / Vol. 84, No. 93 / Tuesday, May 14, 2019 / Notices conduct its third meeting on June 27, 2019. The Commission will evaluate and make recommendations to the U.S. Department of Health and Human Services (HHS) Secretary and Congress regarding improvements to the coordination and leveraging of federal programs related to awareness and clinical care for complex metabolic or autoimmune diseases that result from issues related to insulin that represent a significant disease burden in the United States, which may include complications due to such diseases. DATES: The meeting will take place on June 27, 2019 from 8:00 a.m. to approximately 5:00 p.m. Eastern Time (ET). National Institutes of Health, Building 35, John Edward Porter Neuroscience Research Center [PNRC II], 35 Convent Drive, Bethesda, MD 20892. The meeting will also be held online via webcast. To register to attend the meeting, please visit the registration website at https:// events.kauffmaninc.com/events/nccc3/ index.cfm. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Clydette Powell, Designated Federal Officer, National Clinical Care Commission, U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health, Office of Disease Prevention and Health Promotion, 1101 Wootton Parkway, Suite LL–100, Rockville, MD 20852. Email: OHQ@hhs.gov. Additional information may be obtained at https:// health.gov/hcq/national-clinical-carecommission.asp. The National Clinical Care Commission Act (Pub. L. 115–80) requires the HHS Secretary to establish the National Clinical Care Commission. The Commission will consist of representatives of specific federal agencies and non-federal individuals and entities who represent diverse disciplines and views. The Commission will evaluate and make recommendations to the HHS Secretary and Congress regarding improvements to the coordination and leveraging of federal programs related to awareness and clinical care for complex metabolic or autoimmune diseases that result from issues related to insulin that represent a significant disease burden in the United States, which may include complications due to such diseases. This third meeting of the Commission will consist of presentations by its four subcommittees on their work to support the call for information about federal diabetes programs. The Commission khammond on DSKBBV9HB2PROD with NOTICES SUPPLEMENTARY INFORMATION: VerDate Sep<11>2014 16:57 May 13, 2019 Jkt 247001 members will discuss the work of the subcommittees and overall plan to collect information relevant to its charge. The names and biographies of the Commission members and final meeting agenda will be available prior to the meeting at https://health.gov/hcq/ national-clinical-care-commission.asp. Public Participation at Meeting: The Commission invites public comment on issues related to the Commission’s charge either in-person at the meeting or in writing. In-person attendees who plan to provide oral comments at the Commission meeting during a designated time must submit their comments to OHQ@hhs.gov on or before June 12, 2019 and must check-in on-site. To accommodate as many individuals as possible, the time for each comment will be limited to three minutes. If more requests are received than can be accommodated, speakers will be randomly selected. The nature of the comments will not be considered in making this selection. Written comments are welcome throughout the entire development process of the Commission and may be emailed to OHQ@hhs.gov, or by mail to the following address: Public Commentary, National Clinical Care Commission, 1101 Wootton Parkway, Suite LL–100, Rockville, MD 20852. Written comments should not exceed three pages in length. To attend the Commission meeting, individuals must pre-register at the registration website at https:// events.kauffmaninc.com/events/nccc3/ index.cfm. In-person and live webcast attendance options are available. Inperson attendance at the meeting is limited to space available. In-person registrations will be accepted until maximum capacity is reached and must be completed by June 20, 2019. On the day of the meeting, seating will be provided first to persons who have preregistered. Those who have not preregistered will be accommodated on a first come, first served basis if additional seats are still available 10 minutes before the meeting starts. Individuals who need special assistance, such as sign language interpretation or other reasonable accommodations, should indicate the special accommodation when registering online or by notifying Jennifer Gillissen at jennifer.gillissen@ kauffmaninc.com by June 20, 2019. Authority: The National Clinical Care Commission is required under the National Clinical Care Commission Act (Pub. L. 115–80). The Commission is governed by provisions of the Federal Advisory Committee Act (FACA), Public Law 92–463, as amended (5 U.S.C., App.) which sets forth standards for the PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 formation and use of federal advisory committees. Dated: May 2, 2019. Donald Wright, Deputy Assistant Secretary for Health. [FR Doc. 2019–09920 Filed 5–13–19; 8:45 am] BILLING CODE 4150–32–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Announcement of Meeting of the Secretary’s Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2030 Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, Office of Disease Prevention and Health Promotion ACTION: Notice. AGENCY: The U.S. Department of Health and Human Services (HHS) announces the next meeting of the Secretary’s Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2030 (Committee) regarding the development of national health promotion and disease prevention objectives for 2030. The meeting will be held online via webinar and is open to the public. The Committee will discuss the nation’s proposed health promotion and disease prevention objectives and will provide recommendations to improve health status and reduce health risks for the nation by the year 2030. The Committee will deliberate and prioritize its recommendations for implementing the Healthy People 2030 objectives and develop recommendations regarding graphics for communicating key Healthy People 2030 elements. Pursuant to the Committee’s charter, the Committee’s advice must assist the Secretary in reducing the number of objectives while ensuring that the selection criteria identifies the most critical public health issues that are high-impact priorities supported by current national data. DATES: The Committee will meet on June 26, 2019, from 12:00 p.m. to 4:00 p.m. Eastern Time (ET). ADDRESSES: The meeting will be held online via webinar. Registration for the June 26, 2019 meeting will open on May 23, 2019 at the Healthy People website at http://www.healthypeople.gov. FOR FURTHER INFORMATION CONTACT: Emmeline Ochiai, Designated Federal Officer, Secretary’s Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2030, U.S. Department of Health and Human SUMMARY: E:\FR\FM\14MYN1.SGM 14MYN1

Agencies

[Federal Register Volume 84, Number 93 (Tuesday, May 14, 2019)]
[Notices]
[Pages 21347-21348]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-09920]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Announcement of Meeting of the National Clinical Care Commission

AGENCY: Office of Disease Prevention and Health Promotion, Office of 
the Assistant Secretary for Health, Office of the Secretary, Department 
of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Clinical Care Commission (the Commission) will

[[Page 21348]]

conduct its third meeting on June 27, 2019. The Commission will 
evaluate and make recommendations to the U.S. Department of Health and 
Human Services (HHS) Secretary and Congress regarding improvements to 
the coordination and leveraging of federal programs related to 
awareness and clinical care for complex metabolic or autoimmune 
diseases that result from issues related to insulin that represent a 
significant disease burden in the United States, which may include 
complications due to such diseases.

DATES: The meeting will take place on June 27, 2019 from 8:00 a.m. to 
approximately 5:00 p.m. Eastern Time (ET).

ADDRESSES: National Institutes of Health, Building 35, John Edward 
Porter Neuroscience Research Center [PNRC II], 35 Convent Drive, 
Bethesda, MD 20892. The meeting will also be held online via webcast. 
To register to attend the meeting, please visit the registration 
website at https://events.kauffmaninc.com/events/nccc3/index.cfm.

FOR FURTHER INFORMATION CONTACT: Clydette Powell, Designated Federal 
Officer, National Clinical Care Commission, U.S. Department of Health 
and Human Services, Office of the Assistant Secretary for Health, 
Office of Disease Prevention and Health Promotion, 1101 Wootton 
Parkway, Suite LL-100, Rockville, MD 20852. Email: [email protected]. 
Additional information may be obtained at https://health.gov/hcq/national-clinical-care-commission.asp.

SUPPLEMENTARY INFORMATION: The National Clinical Care Commission Act 
(Pub. L. 115-80) requires the HHS Secretary to establish the National 
Clinical Care Commission. The Commission will consist of 
representatives of specific federal agencies and non-federal 
individuals and entities who represent diverse disciplines and views. 
The Commission will evaluate and make recommendations to the HHS 
Secretary and Congress regarding improvements to the coordination and 
leveraging of federal programs related to awareness and clinical care 
for complex metabolic or autoimmune diseases that result from issues 
related to insulin that represent a significant disease burden in the 
United States, which may include complications due to such diseases.
    This third meeting of the Commission will consist of presentations 
by its four subcommittees on their work to support the call for 
information about federal diabetes programs. The Commission members 
will discuss the work of the subcommittees and overall plan to collect 
information relevant to its charge. The names and biographies of the 
Commission members and final meeting agenda will be available prior to 
the meeting at https://health.gov/hcq/national-clinical-care-commission.asp.
    Public Participation at Meeting: The Commission invites public 
comment on issues related to the Commission's charge either in-person 
at the meeting or in writing. In-person attendees who plan to provide 
oral comments at the Commission meeting during a designated time must 
submit their comments to [email protected] on or before June 12, 2019 and 
must check-in on-site. To accommodate as many individuals as possible, 
the time for each comment will be limited to three minutes. If more 
requests are received than can be accommodated, speakers will be 
randomly selected. The nature of the comments will not be considered in 
making this selection. Written comments are welcome throughout the 
entire development process of the Commission and may be emailed to 
[email protected], or by mail to the following address: Public Commentary, 
National Clinical Care Commission, 1101 Wootton Parkway, Suite LL-100, 
Rockville, MD 20852. Written comments should not exceed three pages in 
length.
    To attend the Commission meeting, individuals must pre-register at 
the registration website at https://events.kauffmaninc.com/events/nccc3/index.cfm. In-person and live webcast attendance options are 
available. In-person attendance at the meeting is limited to space 
available. In-person registrations will be accepted until maximum 
capacity is reached and must be completed by June 20, 2019. On the day 
of the meeting, seating will be provided first to persons who have pre-
registered. Those who have not pre-registered will be accommodated on a 
first come, first served basis if additional seats are still available 
10 minutes before the meeting starts. Individuals who need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should indicate the special accommodation when 
registering online or by notifying Jennifer Gillissen at 
[email protected] by June 20, 2019.
    Authority: The National Clinical Care Commission is required under 
the National Clinical Care Commission Act (Pub. L. 115-80). The 
Commission is governed by provisions of the Federal Advisory Committee 
Act (FACA), Public Law 92-463, as amended (5 U.S.C., App.) which sets 
forth standards for the formation and use of federal advisory 
committees.

    Dated: May 2, 2019.
Donald Wright,
Deputy Assistant Secretary for Health.
[FR Doc. 2019-09920 Filed 5-13-19; 8:45 am]
 BILLING CODE 4150-32-P